Traitements2programmes
Essais1liés
Publications2liées
SourceDBlocale

Traitements

2
MoléculeIndication / populationPhaseObjectifPaysRésultat
ApitegromabA randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD Myopathies Phase 2 À vérifier United States À vérifier
ApitegromabA randomized Phase 2 study to evaluate the efficacy and safety of apitegromab as a monotherapy in participant with FSHD Myopathies Phase 2 À vérifier United States À vérifier

Essais cliniques

1
MoléculeIndication / populationPhaseNCTTitreStatut
Apitegromab Myopathies Phase 2 NCT07435129 Phase 2 Study Evaluating Apitegromab for the Treatment of FSHD RECRUITING

Publications

2
MoléculeIndication / populationTitreJournalDate
Apitegromab Advancing treatment of spinal muscular atrophy through inhibition of the myostatin signaling pathway. Expert review of neurotherapeutics
Apitegromab Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nature medicine